Genitourinary Neoplasms Clinical Trial
Official title:
Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience
| NCT number | NCT02557230 |
| Other study ID # | Ped GU Tumors |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 2016 |
| Est. completion date | April 2024 |
| Verified date | July 2023 |
| Source | Assiut University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with one of genitourinary tumors & treatment outcomes in these patients.
| Status | Recruiting |
| Enrollment | 250 |
| Est. completion date | April 2024 |
| Est. primary completion date | March 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A to 18 Years |
| Eligibility | Inclusion Criteria: - Patients whose age less than or equal to 18 years. - Patients diagnosed with any of neoplasms affecting the genitourinary system. Exclusion Criteria: - Patients whose age more than 18 years. |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Assiut University | Assiut |
| Lead Sponsor | Collaborator |
|---|---|
| Assiut University |
Egypt,
Denes FT, Duarte RJ, Cristofani LM, Lopes RI. Pediatric genitourinary oncology. Front Pediatr. 2013 Dec 16;1:48. doi: 10.3389/fped.2013.00048. — View Citation
Lambert S. Adult Survivors of Pediatric Genitourinary Tumors. In: Wood HM, Wood D, editors. Transition and Lifelong Care in Congenital Urology: Springer International Publishing; 2015. p. 209-16.
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall survival (OS) | Time from the date of initiation of treatment until death from any cause | Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years | |
| Primary | Event Free Survival (EFS) | Time from the date of initiation of treatment until disease progression, or death for any reason. | Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years |